85118-29-2 Usage
Description
9-[3-(dimethylamino)propyl]-9,10-dihydro-10,10-dimethylanthracene-9-ol, also known as Melitracen, is a metabolite of Melitracen Hydrochloride (M215500), an antidepressant medication. It is a chemical compound with a unique structure that includes an anthracene core, a dimethylaminopropyl side chain, and a hydroxyl group. 9-[3-(dimethylamino)propyl]-9,10-dihydro-10,10-dimethylanthracene-9-ol is of interest in the field of pharmaceuticals due to its potential therapeutic properties.
Uses
Used in Pharmaceutical Industry:
9-[3-(dimethylamino)propyl]-9,10-dihydro-10,10-dimethylanthracene-9-ol is used as an active metabolite for the treatment of depression. As a metabolite of Melitracen Hydrochloride, it contributes to the overall therapeutic effect of the antidepressant medication, potentially modulating neurotransmitter levels and improving mood in patients suffering from depressive disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 85118-29-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,5,1,1 and 8 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 85118-29:
(7*8)+(6*5)+(5*1)+(4*1)+(3*8)+(2*2)+(1*9)=132
132 % 10 = 2
So 85118-29-2 is a valid CAS Registry Number.
InChI:InChI=1/C21H27NO/c1-20(2)16-10-5-7-12-18(16)21(23,14-9-15-22(3)4)19-13-8-6-11-17(19)20/h5-8,10-13,23H,9,14-15H2,1-4H3
85118-29-2Relevant articles and documents
Redesign of a Grignard-Based Active Pharmaceutical Ingredient (API) Batch Synthesis to a Flow Process for the Preparation of Melitracen HCl
Pedersen, Michael J.,Skovby, Tommy,Mealy, Michael J.,Dam-Johansen, Kim,Kiil, S?ren
, p. 228 - 235 (2018)
A Grignard-based batch process, for the preparation of Melitracen HCl, has been redesigned to fit a continuous reactor system. The Grignard addition is carried out at room temperature, with subsequent hydrolysis of the magnesium alkoxide intermediate followed by dehydration of the resulting alcohol. The product undergoes further workup by simple gravimetric phase separation and then crystallization with 2 M HCl in diethyl ether to afford pure Melitracen HCl. All steps in the laboratory setup were concatenated, and the setup was proven capable of producing a significant portion of the commercial quantities of Melitracen HCl. The flow setup profits from a reduced footprint, lower energy consumption, fewer synthetic steps, and reduced raw material usage compared to the batch process.
